{
    "root": "316974bf-2b6d-9d66-e063-6294a90a33a9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Zytiga",
    "value": "20250328",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "ABIRATERONE ACETATE",
            "code": "EM5OCB9YJ6"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "zytiga indicated combination prednisone treatment patients metastatic castration-resistant prostate cancer ( crpc ) metastatic high-risk castration-sensitive prostate cancer ( cspc )",
    "contraindications": "metastatic castration-resistant prostate cancer : zytiga 1,000 mg orally daily prednisone 5 mg orally twice daily . ( 2.1 ) metastatic castration-sensitive prostate cancer : zytiga 1,000 mg orally daily prednisone 5 mg orally daily . ( 2.2 ) patients receiving zytiga also receive gonadotropin-releasing hormone ( gnrh ) analog concurrently bilateral orchiectomy . zytiga tablets must taken single dose daily empty stomach . eat food 2 hours 1 hour taking zytiga . tablets must swallowed whole water . crush chew tablets . ( 2.3 ) dose modification : patients baseline moderate hepatic impairment ( child-pugh class b ) , reduce zytiga starting dose 250 mg daily . ( 2.4 ) patients develop hepatotoxicity treatment , hold zytiga recovery . retreatment may initiated reduced dose . zytiga discontinued patients develop severe hepatotoxicity . ( 2.4 )",
    "warningsAndPrecautions": "zytiga \u00ae ( abiraterone acetate ) tablets available strengths packages listed : zytiga \u00ae 500 mg film-coated tablets purple , oval-shaped tablets debossed `` aa `` one side `` 500 `` side . ndc 57894-195-06 , 60 tablets available child-resistant high-density polyethylene bottles zytiga \u00ae 250 mg uncoated tablets white off-white , oval-shaped tablets debossed `` aa250 `` one side . ndc 57894-150-12 , 120 tablets available child-resistant high-density polyethylene bottles",
    "adverseReactions": "none .",
    "indications_original": "ZYTIGA is indicated in combination with prednisone for the treatment of patients with\n                  \n                     Metastatic castration-resistant prostate cancer (CRPC)\n                     Metastatic high-risk castration-sensitive prostate cancer (CSPC)",
    "contraindications_original": "Metastatic castration-resistant prostate cancer: ZYTIGA 1,000 mg orally once daily with prednisone 5 mg orally twice daily. ( 2.1 ) Metastatic castration-sensitive prostate cancer: ZYTIGA 1,000 mg orally once daily with prednisone 5 mg orally once daily. ( 2.2 ) Patients receiving ZYTIGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ZYTIGA tablets must be taken as a single dose once daily on an empty stomach. Do not eat food 2 hours before and 1 hour after taking ZYTIGA. The tablets must be swallowed whole with water. Do not crush or chew tablets. ( 2.3 ) Dose Modification: For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the ZYTIGA starting dose to 250 mg once daily. ( 2.4 ) For patients who develop hepatotoxicity during treatment, hold ZYTIGA until recovery. Retreatment may be initiated at a reduced dose. ZYTIGA should be discontinued if patients develop severe hepatotoxicity. ( 2.4 )",
    "warningsAndPrecautions_original": "ZYTIGA\n  \u00ae (abiraterone acetate) Tablets are available in the strengths and packages listed below:\n \n                  \n                     \n                        ZYTIGA\n    \u00ae 500 mg film-coated Tablets \n   \n                        \n\tPurple, oval-shaped tablets debossed with \"AA\" one side and \"500\" on the other side.\n   \n\tNDC 57894-195-06, 60 tablets available in child-resistant high-density polyethylene bottles\n  \n                     \n                        ZYTIGA\n                        \u00ae\n                        250 mg uncoated Tablets\n                        \n\tWhite to off-white, oval-shaped tablets debossed with \"AA250\" on one side.\n   \n\tNDC 57894-150-12, 120 tablets available in child-resistant high-density polyethylene bottles",
    "adverseReactions_original": "None."
}